Scarica l'app Stockscreener
3.825
0.39%
-0.015
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Precedente Chiudi:
$3.84
Aprire:
$3.95
Volume 24 ore:
740.75K
Relative Volume:
0.62
Capitalizzazione di mercato:
$362.12M
Reddito:
$26.87M
Utile/perdita netta:
$-124.13M
Rapporto P/E:
-2.2011
EPS:
-1.7378
Flusso di cassa netto:
$-125.60M
1 W Prestazione:
+7.44%
1M Prestazione:
-23.65%
6M Prestazione:
+58.06%
1 anno Prestazione:
+104.55%
Intervallo 1D:
$3.815
$3.95
Intervallo di 1 settimana:
$3.54
$4.04
Portata 52W:
$1.212
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Nome
Zentalis Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 263-4333
Indirizzo
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
3.825 | 363.54M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Ripresa | Wells Fargo | Equal Weight |
| 2024-08-12 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2024-06-20 | Downgrade | UBS | Buy → Neutral |
| 2024-06-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-06-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Downgrade | Wedbush | Neutral → Underperform |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Iniziato | Cowen | Outperform |
| 2022-04-06 | Iniziato | Wells Fargo | Overweight |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-29 | Iniziato | Oppenheimer | Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-01-20 | Iniziato | Wedbush | Outperform |
| 2020-09-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-28 | Iniziato | Guggenheim | Buy |
| 2020-04-28 | Iniziato | Jefferies | Buy |
| 2020-04-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
Zentalis Pharmaceuticals(ZNTL.US) 10% Shareholder Buys US$15.17 Million in Common Stock - Moomoo
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock - MarketBeat
Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock - Investing.com
Nearly one-fifth of Zentalis (NASDAQ: ZNTL) sits with one investor group - Stock Titan
Zentalis Pharma closes $92.6 million public offering - The Pharma Letter
New Form 4 Open market buy - Moomoo
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals closes $92.6 million stock offering - Investing.com
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Zentalis Pharmaceuticals Announces Closing of Underwritten - GlobeNewswire
GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering - lw.com
symbol__ Stock Quote Price and Forecast - CNN
Why is Zentalis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Why is Zentalis Pharmaceuticals stock tumbling today? - Investing.com
Zentalis Pharmaceuticals Shares Fall on Public Offering Pricing - Moomoo
Zentalis Pharmaceuticals (ZNTL) Prices $80.5M Public Offering to Fund Clinical Trials - GuruFocus
Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 - Investing.com
Zentalis Pharmaceuticals Prices $80.5 Million Public Offering of Common Stock - Quiver Quantitative
Zentalis Sets $3.50 Share Price to Fund Clinical Trials - Stock Titan
Zentalis Pharmaceuticals Announces Pricing Of Underwritten Public Offering - TradingView
Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis - Stock Titan
Zentalis Pharmaceuticals announces public stock offering By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals announces public stock offering - Investing.com
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering - TradingView
Zentalis Pharmaceuticals stock falls on public offering news By Investing.com - Investing.com Nigeria
Zentalis Pharmaceuticals stock falls on public offering news - Investing.com
Mizuho Securities Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Analysts Decrease Earnings Estimates for ZNTL - MarketBeat
Zentalis Pharmaceuticals (ZNTL) Slips to $4.15 Amid Cautious Biotech TradingDemand Zone - dars.gov.et
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen - MarketBeat
Morgan Stanley Maintains Zentalis Pharmaceuticals(ZNTL.US) With Hold Rating, Raises Target Price to $5 - Moomoo
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Zentalis Highlights Q2 Results and Azenosertib Progress - The Globe and Mail
Wedbush Adjusts Price Target on Zentalis Pharmaceuticals to $5 From $4, Maintains Neutral Rating - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.44, Implies 49% Upside - TradingView
Morgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating - marketscreener.com
Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results - MarketBeat
ZNTL Advances Clinical Trials for Ovarian Cancer Drug Amid Valua - GuruFocus
Zentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary - TradingView
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Zentalis Q2 FY26 net loss widens to $42.29 million - Bitget
ZNTL: Clinical and regulatory progress advances, with $174.6M cash runway into late 2027 despite higher losses - TradingView
ZNTL: Q2 2026 net loss widened to $42.3M as R&D spending rose for late-stage azenosertib trials - TradingView
BlackRock, Inc. Expands Stake in Zentalis Pharmaceuticals (ZNTL) with Strategic Share Addition - GuruFocus
ZNTL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Zentalis Pharmaceuticals Inc Azioni (ZNTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):